肾脏疾病
基质gla蛋白
医学
维生素K2
维生素D与神经学
钙化
肾功能
内科学
内分泌学
维生素
肾
高磷血症
作者
Stefanos Roumeliotis,Vassilios Liakopoulos,Leon J. Schurgers
出处
期刊:Current Vascular Pharmacology
[Bentham Science]
日期:2022-02-10
卷期号:20 (2): 121-126
被引量:7
标识
DOI:10.2174/1570161120666220209145341
摘要
Vascular calcification (VC) is highly prevalent in Chronic Kidney Disease (CKD) patients, progresses gradually with deterioration of kidney function and is a strong, independent predictor of cardiovascular (CV) mortality. Matrix Gla Protein (MGP), the most potent inhibitor of VC, requires vitamin K as a co-factor to become biologically active. Accumulating epidemiological data have associated vitamin K depletion with VC progression and CV outcomes. CKD patients are characterized by poor vitamin K status and at the same time, pronounced CV calcification. In early and advanced CKD, including end-stage kidney disease, exogenous supplementation of vitamin K (especially with menaquinone 7, its most bioavailable form) might decrease the inactive form of MGP (dephosphorylated, uncarboxylated MGP) and probably retard the progression or even reverse VC. Here, we focus and discuss the interventional human studies of vitamin K supplementation in CKD patients and suggest future directions in this area of interest.
科研通智能强力驱动
Strongly Powered by AbleSci AI